Assurex Health, a personalized medicine company, has secured a $25 million term and revolving credit facility from GE Capital and Silicon Valley Bank to support increasing clinical adoption of its GeneSight products, which measure and analyze important genomic variants affecting the metabolism and response to behavioral health medications in individual patients. Existing investors provided an additional $7 million to complete the $32 million financing. The funds will also allow the company to add proven genetic variants and new medications to its products, as well as continue to support its growth trajectory.
Assurex provides genetic information to help physicians select the right medication for patients with depression, anxiety, chronic pain, ADHD and other neuropsychiatric disorders. It last raised $12.5 million—through a Series C round led by Sequoia Capital, Four Rivers Group and Claremont Creek Ventures—at a $79 million valuation in May 2012.